News dal mondo
24
Feb
Industry clamors for clearer guidance on transition to ICH M4Q(R2)
The pharmaceutical industry has expressed a need for greater clarity regarding the timeline for converting quality information for new and existing drug and biologics dossiers to the common technical document (CTD) format described in the International Council for Harmonisation’s (ICH) M4Q(R2) guideline.
These were among the many concerns raised by the EU pharmaceutical industry in their feedback submitted in response to the European Medicines Agency’s (EMA) request for comment on the M4Q(R2) guideline. The guideline was published by ICH in May 2025.. [EMA]
18
Giu
AIFA Sistema informatico Workflow Officine Materie Prime - Ulteriore Aggiornamento tecnico 18 maggio 2026
Formati files ammessi: PDF editabile o p7m. Scansioni a 200 dpi, anche in bianco e nero, per ottimizzare...
15
Mag
US FDA’s New AI-Informed Inspection Pilot and What It Means for Industry
We have written on this blog about FDA’s modernization agenda from several angles lately—from...
15
Mag
EU Regulators discuss new pharma legislation, AI, and more
A panel of European regulators answered questions during a town panel discussion at RAPS Euro Convergence...
15
Mag
US FDA official details top observations from QMSR inspections
The top observations identified in Form 483 reports from inspections conducted under the recently implemented...
le ultime news
19 Mar
Nuove norme UE sui farmaci: più incentivi all’innovazione e controllo della disponibilità
19 Mar
As Iran war squeezes Middle East drug shipments, experts warn of longer-term effects on US manufacturing, generics
19 Mar
Farmalabor: investiti 8,5 milioni in un progetto per le malattie rare
17 Mar
EMA Management Board: highlights of March 2026 meeting
13 Mar
Dal China all’India-shoring, il rischio di una nuova dipendenza
11 Mar
EU Finalizes Pharma Reform Package, Clarifies New Rules On Modular Market Protection
11 Mar
PFAS restriction proposal: ECHA’s Socio-Economic Analysis Committee agrees its draft opinion
11 Mar
Farmaci - Gemmato: In cantiere anche un ritorno nazionale alla chimica farmaceutica di base